Table 2. Association between CENPL expression and clinicopathologic characteristics (logistic regression).

Clinical characteristics	Total	OR	P-value
Age at diagnosis (years) (>40 vs. ≤40)	370	0.9 (0.4–1.8)	0.719
Gender (female vs. male)	371	0.6 (0.4–1.0)	0.033
Family history (no vs. yes)	320	0.6 (0.4–0.9)	0.020
Histologic grade (G3-4 vs. G1-2)	366	3.4 (2.2–5.4)	0.000
Clinical stage (III-IV vs. I-II)	347	1.7 (1.1–2.8)	0.026
T (T3-4 vs. T1-2)	368	1.8 (1.1–3.0)	0.012
N (N1 vs. N0)	256	1.0 (0.1–8.4)	1.000
M (M1 vs. M0)	270	1.0 (0.1–8.4)	1.000
Residual tumor (R1-2 vs. R0)	342	1.6 (0.6–4.5)	0.337
Tumor status (with tumor vs. tumor free)	352	1.6 (1.0–2.4)	0.041
Vascular invasion (yes vs. no)	315	1.5 (1.0–2.5)	0.070
Child-Pugh (B-C vs. A)	239	1.6 (0.6–4.5)	0.337
New tumor event (yes vs. no)	350	1.4 (0.9–2.2)	0.109
Radiation therapy (yes vs. no)	346	0.6 (0.1–2.5)	0.479
Postoperative ablation embolization (yes vs. no)	347	1.2 (0.5–2.6)	0.682
Risk factor
RF2 vs. RF1	235	1.3 (0.8–2.2)	0.319
RF3 vs. RF1	199	1.2 (0.7–2.1)	0.600
RF4 vs. RF1	160	0.5 (0.2–1.1)	0.095
RF3 vs. RF2	192	0.9 (0.5–1.6)	0.712
RF4 vs. RF2	153	0.4 (0.2–0.9)	0.020
RF4 vs. RF3	117	0.5 (0.2–1.0)	0.051
AFP
AFP2 vs. AFP1	213	2.9 (1.6–5.4)	0.000
AFP3 vs. AFP1	131	4.0 (2.2–7.6)	0.000
AFP3 vs. AFP2	212	1.4 (0.7–2.9)	0.392

Abbreviations: OR: odd ratio; T: topography distribution; N: lymph node metastasis; M: distant metastasis; RF: risk factor (RF1: neither alcohol consumption or viral hepatitis; RF2: viral hepatitis; RF3: alcohol consumption; RF4: both alcohol consumption and viral hepatitis); AFP: alpha fetal protein (AFP1 represents AFP <20; AFP2 represents 20≤ AFP <400; AFP3 represents AFP ≥400).